Estradiol
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Estradiol |
| DrugBank ID | DB00783 |
| Brand Names (EU) | Estradiol, Zoely |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 99.96% |
Approved Indication (EMA)
Oral contraception
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acne (disease) | 99.96% | DL |
| 2 | symptomatic form of fragile X syndrome in female carrier | 98.76% | DL |
| 3 | ovarian remnant syndrome | 98.58% | DL |
| 4 | anovulation | 98.58% | DL |
| 5 | partial trisomy/tetrasomy of the short arm of chromosome 18 | 98.56% | DL |
| 6 | partial trisomy/tetrasomy of the short arm of chromosome 12 | 98.56% | DL |
| 7 | partial trisomy/tetrasomy of the short arm of chromosome 5 | 98.54% | DL |
| 8 | blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome | 98.52% | DL |
| 9 | luteoma of pregnancy | 98.47% | DL |
| 10 | partial autosomal trisomy/tetrasomy | 98.45% | DL |
| 11 | ovarian ectopic pregnancy | 98.44% | DL |
| 12 | primary ovarian failure | 98.44% | DL |
| 13 | blepharophimosis-epicanthus inversus-ptosis | 98.41% | DL |
| 14 | ovarian dysfunction | 98.36% | DL |
| 15 | zinc, elevated plasma | 98.23% | DL |
| 16 | stapes ankylosis with broad thumbs and toes | 98.15% | DL |
| 17 | telecanthus | 98.15% | DL |
| 18 | ovarian hyperstimulation syndrome | 97.48% | DL |
| 19 | sebaceous gland anomaly | 94.61% | DL |
| 20 | pyogenic arthritis-pyoderma gangrenosum-acne syndrome | 93.17% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.